Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 1403 for:    Peru

The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, Peru (PERCAPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01338051
Recruitment Status : Completed
First Posted : April 19, 2011
Last Update Posted : April 21, 2014
Sponsor:
Collaborators:
Peru Instituto Nacional de Enfermadades Neoplasticas (INEN)
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Jerome Belinson, Preventive Oncology International, Inc.

Brief Summary:
This project will use a community based participatory research orientation to develop a model for large scale "campaign" preventive healthcare interventions. The investigators have considerable expertise with cervical cancer screening and HPV vaccination. The investigators also have well tested methodologies for cervical cancer screening that are highly effective, including self-sampling for HPV and improved specimen transport systems. Therefore, the investigators will use these medical interventions as the model preventive health interventions for this project.

Condition or disease Intervention/treatment Phase
Cervical Intraepithelial Neoplasia Cervical Cancer Cervical Neoplasm Cervical Dysplasia Human Papillomavirus Biological: Gardasil Phase 1

Detailed Description:
Our research group has recently demonstrated that a self-collected cervico-vaginal sample tested with a very high throughput HR-HPV assay is as sensitive has a direct endocervical physician collected sample. Teamed with a non-liquid transport media the investigators believe the technology is solved to reach large populations in a short period of time. With the majority of the world's medically underserved now living in middle income countries it is not necessary to think simple and small to reach the Earth's needy. The investigators can think high tech and high throughput. The massive volumes possible, with proper organization, will control the per/patient cost. The investigators will think "events", not continuous care. Clearly continuous care is the only way to adequately provide the needed care for many problems. However, many interventions can be confined to events which organize large screening or vaccination days and only when positives are identified from the detection algorithm does the healthcare staff become involved for management. The investigators spend an enormous amount of resources identifying the majority of people who will ultimately test negative. The more local the paradigms and the more involved the community in designing the program, the greater will be the participation and the lost to follow-up segment will shrink. This mother, child, screen, treat and vaccinate program will use cervical cancer prevention as the target preventive healthcare intervention. Using community based research orientation the project will begin with a 3 day education program and collaborative meeting with the women leaders of the communities (promotoras). Collectively the investigators will develop the model for the community to advertise, educate, recruit, register, self-collect the specimens, deliver the samples, and report the results. In addition the logistics of the 3 vaccination schedule for the female children will be organized. The medical staff will be involved only with the management of the positives and the vaccine administration. The observational measures will focus on assessing how effectively each of the steps was accomplished.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 642 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, Peru (PERCAPS)
Study Start Date : May 2011
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine



Intervention Details:
  • Biological: Gardasil

    Gardasil will be administered to 10-13 year old daughters and granddaughters of study participants according to manufacturers recommended schedule of administration. Gardasil is supplied as 0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months.

    DOSAGE FORMS AND STRENGTHS • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe.



Primary Outcome Measures :
  1. Evaluation of key study processes used in the process of implementing a mother/child screen, treat and vaccinate program in Iquitos, Peru. [ Time Frame: Interview with participants will occur at approximately one month after 2nd vaccination ]
    The investigators will evaluate community participation, lost to follow up and potential sustainability. One on one interviews with participants will be conducted by trained medical staff. Additional measures to success will be gathered from interviews with promotoras, participating health services staff and recoeded observation. These analyses are descriptive in nature.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Inclusion criteria (adult)

  1. Non pregnant women 30-45 years of age in Manchay, and in Iquitos, with female children or grandchildren ages 10-13 who they are willing to enroll in the study to receive Gardasil vaccination.
  2. No screening or knowledge of the results of a Pap Test in the last 5 years
  3. No hysterectomy
  4. No prior pelvic radiation.
  5. Willing to sign consent form

Inclusion criteria (children)

  1. Female children and grandchildren of a participating women ages 10-13 years
  2. No acute illnesses (clinically evident according to vaccinating staff) - such as fever, nausea, vomiting, diarrhea
  3. No previous vaccination with Gardasil
  4. No reactions to previous dose in their vaccination series
  5. No known yeast allergy
  6. Willing to participate

Exclusion Criteria:

Exclusion criteria (adults)

Patients will be excluded in the study based on the following criteria:

  1. Males
  2. Women younger than 30 years old and older than 45 years old.
  3. Women without female children or grandchildren age 10-13 or who are unwilling to enroll their 10-13 year old female children or grandchildren to receive Gardasil.
  4. Pregnant women.
  5. Patients with known history of hysterectomy or radiation for a pelvic cancer.
  6. Refusal to participate

Exclusion criteria (Children)

  1. Males
  2. Girls younger than 10 years old, and older than 13 years.
  3. acute illnesses (clinically evident according to vaccinating staff) - such as fever, nausea, vomiting, diarrhea
  4. previous vaccination with Gardasil
  5. reactions to a previous dose in their vaccination series
  6. known yeast allergy
  7. Refusal to participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01338051


Locations
Layout table for location information
Peru
Centro de Salud Portada de Manchay
Manchay, Lima, Peru
Centro de Salud Bellavista Nanay
Iquitos, Loreto, Peru, 065
Sponsors and Collaborators
Preventive Oncology International, Inc.
Peru Instituto Nacional de Enfermadades Neoplasticas (INEN)
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Jerome L Belinson, MD Preventive Oncology International
Principal Investigator: Carlos Vallejos Sologuren, MD Instituto Nacional de Enfermadades Neoplasticas (INEN)

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jerome Belinson, Jerome Belinson MD, president, Preventive Oncology International, Inc.
ClinicalTrials.gov Identifier: NCT01338051     History of Changes
Other Study ID Numbers: PERCAPS I
First Posted: April 19, 2011    Key Record Dates
Last Update Posted: April 21, 2014
Last Verified: April 2014
Keywords provided by Jerome Belinson, Preventive Oncology International, Inc.:
Community based participatory research
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Cervical Intraepithelial Neoplasia
Uterine Cervical Dysplasia
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Carcinoma in Situ
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Precancerous Conditions